Clinical trial
A Randomized, Double-Blind, Multicenter Phase III Clinical Trial of HB0025 Injection Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent Endometrial Cancer
NCT07902999 is registered in ClinicalTrials.gov with Shanghai Huaota Biopharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Multicenter Phase III Clinical Trial of HB0025 Injection Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent Endometrial Cancer
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- October 20, 2026
- Completion date
- June 26, 2031
- Enrollment
- 333 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
first-line pmmr endometrial cancer
Arms
As registered; 2 arms.
-
HB0025
HB0025 combined with Paclitaxel for Injection plus Carboplatin for Injection
-
Placebo
Placebo combined with Paclitaxel for Injection plus Carboplatin for Injection
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Progression-free survival (PFS)
PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the Blinded Independent Central Review or death due to any cause (whichever occurs first)
Lead sponsor's other trials
Shanghai Huaota Biopharmaceutical Co., Ltd., most recent start first.
+13 more trials See the organization page